Vinorelbine derivatives

Details Vinorelbine derivatives Vinorelbine derivatives

2007-04-06

2011-11-08

Jarrell, Noble (Department: 1622)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

08053428

ABSTRACT:
The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.

REFERENCES:
patent: 4307100 (1981-12-01), Langlois et al.
patent: 4347249 (1982-08-01), Potier et al.
patent: 4388305 (1983-06-01), Trouet et al.
patent: 4430269 (1984-02-01), Pearce
patent: 4639456 (1987-01-01), Trouet et al.
patent: 4737586 (1988-04-01), Potier et al.
patent: 4769453 (1988-09-01), Potier et al.
patent: 5047528 (1991-09-01), Kutney et al.
patent: 6127377 (2000-10-01), Duflos et al.
patent: RE37449 (2001-11-01), Kutney et al.
patent: 6365735 (2002-04-01), Rool
patent: 7235564 (2007-06-01), Scott et al.
patent: 7238704 (2007-07-01), Scott et al.
patent: 2004/0186286 (2004-09-01), Fukuyama et al.
patent: 2005/0137169 (2005-06-01), Scott et al.
patent: 2007/0179170 (2007-08-01), Scott et al.
patent: 2007/0179171 (2007-08-01), Scott et al.
patent: 2008/0051425 (2008-02-01), Scott et al.
patent: 2008/0108644 (2008-05-01), Scott et al.
patent: 2008/0119502 (2008-05-01), Wolf et al.
patent: 2008/0125451 (2008-05-01), Wolf et al.
patent: 2458600 (2003-03-01), None
patent: 101108859 (2008-01-01), None
patent: 0292463 (1988-11-01), None
patent: 1 426 377 (2004-06-01), None
patent: 2707988 (1995-01-01), None
patent: 2003-064084 (2003-03-01), None
patent: 8605491 (1986-09-01), None
patent: 2005055943 (2005-06-01), None
patent: WO 2005/055939 (2005-06-01), None
patent: 2008/011805 (2008-01-01), None
patent: 2008/033935 (2008-03-01), None
patent: 2008033930 (2008-03-01), None
“Cancer Definition”, http://www.medterms.com/script/main/art.asp?articlekey=2580, accessed Nov. 27, 2007.
Krikorian et al., Onkologie, 1991, 14, pp. 7-12.
Mathe et al. Cancer Letters, 1985, 27, pp. 285-293.
Bau et al., “Crystal Structure of Vinblastine,” J. Chem. Soc. Perkin Trans. pp. 2079-2082 (2000).
Cros et al., “Experimental Antitumor Activity of Navelbine,” Seminars in Oncology 16(2)(Suppl. 4):15-20 (1989).
Keuhne et al., “Syntheses and Biological Evaluation of Vinblastine Congeners,” Organic and Biomolecular Chemistry 1:2120-36 (2003).
Lavoie et al., “Bioisosterism: A Rational Approach in Drug Design,” Chemical Reviews 96:3147-76 (1996).
Merck Index, “Vindesine,” 9982, 9986, 9987, and 9989.
Moncrief et al., “Structures of Leurocristine (Vincristine) and Vincaleukoblastine X-Ray Analysis of Leurocristine Methiodide,” Journal of American Chemical Society 87(21):4963-4964 (1965).
Neuss et al., “Vinca Alkaloids XXXIII[1]. Microbiological Conversions of Vincaleukoblastine (VLB, Vinblastine), an Antitumor Alkaloid fromVinca rosea,” Helvetica Chimica Acta 57(6):1886-90 (1974).
Sheng et al., “Synthesis and Biological Evaluation of C-12′ Substituted Vinflunine Derivatives,” Bioorganic & Medicinal Chemistry Letters 18:4602-4605 (2008).
Voss et al., “Synthesis and SAR ofVincaAlkaloid Analogues,” Bioorganic & Medicinal Chemistry Letters 19:1245-1249 (2009).
Barthe et al., “Optimization of the Separation ofVincaAlkaloids by Nonaqueous Capillary Electrophoresis,” Journal of Chromatography A 968:241-50 (2002).
International Search Report foro International Patent Application No. PCT/US07/78281 (Sep. 3, 2008).
Sheng et al., “Synthesis and Biological Evaluation of C-12′ Substituted Vinflunine Derivatives,” Shanghai Hengrui Pharmaceutical Co. Ltd. Shanghai China, Poster Presented at 235th ACS National Meeting, New Orleans, LA (Apr. 6-10, 2008).
Berge et al., “Pharmaceutical Salts,”Journal of Pharmaceutical Sciences66(1):1-19 (1997).
Boyd, M.R., “Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval,” Teicher, B. Ed., Humana Press, Totowa, New Jersey, pp. 23-42 (1997).
Skehan et al., “New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening,”Journal of the National Cancer Institute82(13):1107-1112 (1990).
Fahy, J., “Modifications in the << upper >> or Velbenamine Part of theVincaAlkaloids Have Major Implications for Tubulin Interacting Activities,”Current Pharmaceutical Design7:1181-1197 (2001).
Lobert et al., “VincaAlkaloid-Induces Tubulin Spiral Formation Correlates with Cytotoxicity in the Leukemic L1210 Cell Line,”Biochemistry39:12053-12062 (2000).
Ram & Kumari, “Natural Products of Plant Origin as Anticancer Agents,”Drug News Perspect14(8):465-482 (2001).
CAS(R) Registry No. 81600-06-8, Nov. 16, 1984.
CAS(R) Registry No. 123286-01-1; 123286-00-0, Oct. 20, 1999.
CAS(R) Registry No. 67699-41-6; 67699-40-5, Nov. 16, 1984.
Anhydrovinblastine,Pioneer,© IMSworld Publications Ltd (2000) (Update Date May 8, 2000).
Vinxaltine: S 12363,Pioneer,© IMSworld Publications Ltd (2000 (Update Date May 22, 1995).
Vinflunine; F 12158; L 0070,Pioneer,© IMSworld Publications Ltd (2000 (Update Date Apr. 19, 1999).
Napavin,Pioneer,© IMSworld Publications Ltd (2000 (Update Date Oct. 25, 1999).
Registry No. 166533-14-8,SciFinder(Feb. 28, 2002).
Registry No. 105801-71-6,SciFinder(Feb. 28, 2002).
Registry No. 105801-70-5,SciFinder(Feb. 28, 2002).
Registry No. 108893-99-8,SciFinder(Feb. 28, 2002).
Registry No. 108893-98-7,SciFinder(Feb. 28, 2002).
Registry No. 218128-76-8,SciFinder(Feb. 28, 2002).
Registry No. 54112-69-5,SciFinder(Feb. 28, 2002).
Registry No. 108893-97-6,SciFinder(Feb. 28, 2002).
Registry No. 108893-96-5,SciFinder(Feb. 28, 2002).
Registry No. 90012-98-9,SciFinder(Feb. 28, 2002).
Registry No. 90012-97-8,SciFinder(Feb. 28, 2002).
Supplementary European Search Report for European Patent Application No. EP04813161 (May 13, 2009).
Yamaguchi et al., “Identification of Novel Metabolites of Vinorelbine in Rat,” Xenobiotica 28(3):281-91 (1998) Abstract.

Affiliated with

Also associated with

Rating

Vinorelbine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vinorelbine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vinorelbine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4277837